The Efficacy and Safety of Iodine-125 Brachytherapy Combined with Chemotherapy in Treatment of Advanced Lung Cancer: a Meta-analysis. | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2017]

Author(s):

1. Hui Qiu: Department of Radiotherapy, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China

2. Jiayin Ji: Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China

3. Zhiying Shao: Department of Internal Medicine Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China

4. Jianshe Wang: Department of Radiotherapy, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China

5. Gaolei Ma: Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China

6. Longzhen Zhang: Department of Radiotherapy, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China; Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu, P.R. China

Abstract:

The aim of this study was to systematically review the efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in patients with advanced lung cancer. PubMed, MEDLINE, EBSCO, FMJS and Web of Science were searched to obtain randomized controlled trials (RCTs), published in English and Chinese, until February 2016. The evaluating indicators were complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), overall response rate (ORR), disease control rate (DCR), one-year overall survival, two-year overall survival and adverse events. Revman 5.2 software was used for data syntheses and analyses. A total of 296 patients enrolled in 5 RCTs were ultimately included in this study based on our selection criteria, and 150 patients received chemotherapy alone, while another 146 patients received the combination therapy of iodine-125 brachytherapy and chemotherapy. The results showed that iodine-125 brachytherapy combined with chemotherapy was superior to chemotherapy alone in CR (risk ratio [RR] = 3.66, 95% confidence interval [CI]: 2.08 to 6.44, p<0.001), PR (RR = 1.47, 95% CI: 1.16 to 1.86, p=0.001), ORR (RR = 1.85, 95% CI: 1.54 to 2.22, p<0.001), DCR (RR = 1.19, 95% CI: 1.10 to 1.29, p<0.001), one-year overall survival (RR = 1.46, 95% CI: 1.12 to 1.92, p=0.006) and PD (RR = 0.20, 95% CI: 0.09 to 0.43, p<0.001); meanwhile, there was no significant difference in two-year overall survival (RR = 1.30, 95% CI: 0.72 to 2.37, p=0.39). In terms of adverse events, the combination therapy significantly increased the incidence of pneumothorax (RR = 4.93, 95% CI: 1.94 to 12.55, p=<0.001); however, no significant differences were found in the incidence of other adverse events. This study indicated that the combination therapy of iodine-125 brachytherapy and chemotherapy could improve the therapeutic efficacy of advanced lung cancer without increasing the incidence of adverse events, except pneumothorax.

Page(s): 237-245

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 4, Year: 2017

Keywords:

Keywords are not available for this article.

References:

[1] SiegelRL,MillerKD,JemalA, 2015.,CA Cancer J Clin 65 5 -29

[2] JohnLD, 2010.Self-care strategies used by patients with lung cancer to promote quality of life,Oncol Nurs Forum 37 339 -47

[3] WagnerTD,YangGY, 2010.The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC),Curr Drug Targets 11 67 -73

[4] DentonE,ConronM., 2016.Improving outcomes in lung cancer: The value of the multidisciplinary healthcare team,J Multidiscip Health 9 137 -44

[5] PolanskiJ,Jankowska-PolanskaB,RosinczukJ,ChabowskiM,Szymanska-ChabowskaA, 2016.Quality of life of patients with lung cancer,Oncol Targets Ther 9 1023 -8

[6] SkowronekJ., 2015.Brachytherapy in the treatment of lung cancer - a valuable solution,J Contemp Brachytherapy 7 297 -311

[7] ReveizL,RuedaJR,CardonaAF, 2012.Palliative endobronchial brachytherapy for non-small cell lung cancer,Cochrane Database Syst Rev 12 CD004284 -

[8] ZuberS,WeissS,BaaskeD,SchopeM,StevensS,BodisS, 2015.-125 seed brachytherapy for early stage prostate cancer: A single-institution review,Radiat Oncol 10 49 -

[9] LiuB,ZhouT,GengJ,ZhangF,WangJ,LiY., 2015.Percutaneous computed tomography-guided iodine-125 seeds implantation for unresectable pancreatic cancer,Indian J Cancer 52 e69 -74

[10] LuoYJ,LiuZL,YePC,FuZM,LuF,SuleimanAA, 2015.Safety and efficacy of intraoperative iodine-125 seed implantation brachytherapy for rectal cancer patients: A prospective clinical research,J Gastroenterol Hepatol -

[11] LiJ,XieQ,WangW,HuaY,ChengY,LiL, 2016.CT-guided implantation of (125)I seeds (permanent brachytherapy) for metastatic tumors of the hepatic portal system: Effectiveness and safety in 13 patients,Brachytherapy 15 224 -30

[12] MonkBJ,TewariKS,PuthawalaAA,SyedAM,HaugenJA,BurgerRA, 2002.Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation,Int J Radiat Oncol Biol Phys 52 806 -15

[13] FleischmanEH,KaganAR,StreeterOE,TyrellJ,WollinM,LeagreCA, 1992.-125 interstitial brachytherapy in the treatment of carcinoma of the lung,J Surg Oncol 49 25 -8

[14] JiangG,LiZ,DingA,ZhouF,JiaoW,TangD, 2015.Computed tomography-guided iodine-125 interstitial implantation as an alternative treatment option for lung cancer,Indian J Cancer 51 e9 -12

[15] SenanS,LagerwaardFJ,de PanC,SipkemaD,BurgersSA,MurrerLH, 2000.A CT-assisted method of dosimetry in brachytherapy of lung cancer,Radiother Oncol 55 75 -80

[16] FernandoHC,LandreneauRJ,MandrekarSJ,NicholsFC,HillmanSL,HeronDE, 2014.Impact of brachytherapy on local recurrence rates after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer,J Clin Oncol 32 2456 -62

[17] NishinoM,JackmanDM,HatabuH,YeapBY,CioffrediLA, ., -

[18] ShimizuT,SaijoN., 2003.Common toxicity criteria: Version 2.0, an improved reference for grading the adverse reaction of cancer treatment,Nihon Rinsho 61 937 -42

[19] CoxJD,StetzJ,PajakTF, 1995.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC),Int J Radiat Oncol Biol Phys 31 1341 -6

[20] MoherD,LiberatiA,TetzlaffJ,AltmanDG, 2009.Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement,J Clin Epidemiol 62 1006 -12

[21] ZhangT,LuM,PengS,ZhangW,YangG,LiuZ, 2014.CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy,J Cancer Res Clin Oncol 140 1383 -90

[22] ZhangS,ZhengY,YuP,YuF,ZhangQ,LvY, 2011.The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer,J Cancer Res Clin Oncol 137 1813 -22

[23] ZhangFJ,LiCX,WuPH,WuYX,JiaoDC,LiuJ, 2007.CT-guided radioactive 125I seed implantation in treating localized advanced pulmonary carcinoma,Zhonghua Yi Xue Za Zhi 87 3272 -5

[24] YuX,LiJ,ZhongX,HeJ, 2015.Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III nonsmall cell lung cancer after concurrent chemoradiotherapy,BMC Cancer 15 656 -

[25] FengY,XiaoYY,LiSD,LinMX,ZhangY,WangHM, 2012.The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine,Chin J Integr Med 18 663 -9

[26] HuckleA,Al-QaisiehB,BownesP, 2012.Methods of verifying the output of the treatment planning system used for high dose rate (HDR) prostate brachytherapy,Radiother Oncol 103 261 -5

[27] Martinez-MongeR,PagolaM,VivasI,Lopez-PicazoJM, 2008.CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC),Lung Cancer 61 209 -13

[28] LiJR,SunY, 2015.Radioactive seed implantation and lobaplatin chemotherapy are safe and effective in treating patients with advanced lung cancer,Asian Pac J Cancer Prev 16 4003 -6

[29] WangZM,LuJ,LiuT,ChenKM,HuangG,LiuFJ, 2011.CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer,Lung Cancer 74 253 -7

[30] ChenHH,JiaRF,YuL,ZhaoMJ,ShaoCL,ChengWY, 2008.Bystander effects induced by continuous low-dose-rate 125I seeds potentiate the killing action of irradiation on human lung cancer cells in vitro,Int J Radiat Oncol Biol Phys 72 1560 -6

[31] MachtayM,PaulusR,MoughanJ,KomakiR,BradleyJE,ChoyH, 2012.Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma,J Thorac Oncol 7 716 -22

[32] BrachB,BuhlerC,HaymanMH,JoynerLR,LiprieSF, 1994.Percutaneous computed tomography-guided fine needle brachytherapy of pulmonary malignancies,Chest 106 268 -74

Citations

Downloads

Views